Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
The Safety of Citrus aurantium (Bitter Orange) and its Primary Protoalkaloid p‐Synephrine
- S. Stohs, Harry G. Preuss, Mohd A. Shara
- Medicine
- Phytotherapy research : PTR
- 1 October 2011
Citrus aurantium (bitter orange) extract and its principal protoalkaloidal constituent p‐synephrine are widely used in weight loss and weight management as well as in sports performance products.… Expand
A 60day double-blind, placebo-controlled safety study involving Citrus aurantium (bitter orange) extract.
- G. Kaats, H. Miller, Harry G. Preuss, S. Stohs
- Chemistry, Medicine
- Food and chemical toxicology : an international…
- 1 May 2013
Bitter orange (Citrus aurantium) extract and its primary protoalkaloid p-synephrine are widely consumed in dietary supplements for weight management and sports performance. p-Synephrine is also… Expand
Stereochemical and pharmacological differences between naturally occurring p-synephrine and synthetic p-synephrine
- S. Stohs, Harry G. Preuss
- Chemistry
- 2012
p-Synephrine, the primary protoalkaloid in Citrus aurantium (bitter orange) and some other Citrus species, exists in nature in the l- or [R-(−)]-enantiomeric form, whereas synthetic p-synephrine is a… Expand
Safety and Efficacy of Banaba–Moringa oleifera–Green Coffee Bean Extracts and Vitamin D3 in a Sustained Release Weight Management Supplement
- S. Stohs, G. Kaats, Harry G. Preuss
- Medicine
- Phytotherapy research : PTR
- 12 February 2016
This 60‐day, 30‐subject pilot study examined a novel combination of ingredients in a unique sustained release (Carbopol matrix) tablet consumed twice daily. The product was composed of extracts of… Expand
Issues regarding a FACT review paper on the efficacy of herbal supplements containing Citrus aurantium and synephrine alkaloids for the management of overweight and obesity
- S. Stohs, Harry G. Preuss, Mohd A. Shara
- Medicine
- 1 March 2013
Issues Associated With the Case Report Entitled “Hypertensive Urgency Associated With Xenadrine EFX Use”
- S. Stohs, Mohd A. Shara, Harry G. Preuss
- Medicine
- Journal of pharmacy practice
- 1 December 2011
A number of issues exist with respect to the case study entitled ‘‘Hypertensive urgency associated with Xenadrine EFX use’’ by Moaddeb et al (J Pharm Pract. June 2011. doi:10:1177/ 0897190011406127).… Expand
Linking fasting blood glucose quartiles of nondiabetic volunteers ages 21–84 years to metabolic syndrome components: focusing on the aging paradox
- Harry G. Preuss, Nate Mrvichin, D. Bagchi, G. Kaats
- Medicine
- 2020
Abstract Background: In recent, limited-in-size, cross-sectional studies employing nondiabetic subjects, fasting blood glucose (FBG) levels were used to estimate status of insulin resistance (IR) and… Expand
Opinion Paper: Using a Body Composition Improvement Index (BCI) to Improve the Assessment of Nutritional Interventions
- G. Kaats, Stephen D. Nugent, S. Stohs, Harry G. Preuss
- Medicine
- 31 July 2016
Flower Pollen Extract and its Effect on the Prostate Randomized Trial of a Combination of Natural Products ( Cernitin , Saw Palmetto , B-Sitosterol , Vitamin E ) on Symptoms of Benign Prostatic…
- Harry G. Preuss, Charlyn Marcusen, J. Regan, I. Klimberg, Timothy A. Welebir, W. A. Jones
- 2017
Because benign prostatic hyperplasia (BPH) is relatively common, it is important to discover safe and effective means to treat this often debilitating perturbation. Accordingly, we examined the… Expand
when non significant results can mask significant results a procedure for using dose related analyses
- G. Kaats, Nate Mrvichin, Stephen D. Nugent, Harry G. Preuss
- Mathematics
- 15 September 2017
Background: Non-significant within-group and between-group comparisons of baseline-ending changes in clinical trials and pilot studies can mask positive changes if dose-related compliance procedures… Expand